Fig. 2From: Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) studyShift in hyperemia severity grading from baseline at week 12 in (a) treatment-naïve and previously treated patients (P ≥ 0.2717 in both groups, compared with baseline), (b) patient subgroups previously treated with prostaglandin analog (PGA) or non-PGA monotherapy (P ≥ 0.2295 in both groups, compared with baseline), and (c) patient subgroups previously treated with latanoprost or travoprost monotherapy (P ≥ 0.1185 in both groups, compared with baseline)Back to article page